GO:0008443 phosphofructokinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008443 phosphofructokinase activity is a molecular_function defined as catalysis of phosphate transfer, usually from ATP, to a phosphofructose substrate.
• Phosphofructokinase-1 (PFK-1) is the committed and rate-limiting enzyme of glycolysis, and its activity is controlled by allosteric effectors and cellular energy status.
• Human PFK-1 is a tetramer assembled from PFKM, PFKL and PFKP subunits, and the subunit composition influences catalytic and regulatory properties.
• Phosphofructokinase activity is altered in metabolic states such as insulin resistance and in cancer, where PFKP can be targeted for degradation.
• In vivo tracing in the myocardium shows that phosphofructokinase activity coordinates biosynthetic pathway activity, linking glycolysis to macromolecule synthesis.
• Experimental study of phosphofructokinase activity uses enzyme assays, structural biology, metabolic tracing and CRISPR-based models of PFK genes.
Description
Phosphofructokinase activity (GO:0008443) is a molecular_function that catalyzes the transfer of a phosphate group, usually from ATP, to a phosphofructose substrate molecule. This activity is best known as the committed step of glycolysis, where fructose-6-phosphate is phosphorylated to fructose-1,6-bisphosphate, and it is a key control point for glucose flux. Because the reaction is essentially irreversible under physiological conditions, it determines whether glucose carbons enter glycolytic catabolism, and it is therefore tightly regulated by energy charge, allosteric effectors and subunit composition. Researchers study phosphofructokinase activity to understand how cells balance ATP production with biosynthetic demand, and how this balance is disrupted in disease. The enzyme is not a single protein in humans: PFK-1 is a tetramer of PFKM, PFKL and PFKP subunits, and the tissue-specific expression of these subunits produces isoenzymes with distinct regulatory behavior. In skeletal muscle, phosphofructokinase activity is sensitive to acidosis and to physiological conditions, which has made it a classic model for studying fatigue and metabolic regulation. In the intestinal mucosa, glucose availability modulates phosphofructokinase activity, illustrating that the enzyme responds to nutritional state. Historically, inhibition of phosphofructokinase activity was linked to the mode of action of trivalent organic antimonials on Schistosoma mansoni, showing that this activity can also be a drug target in parasites. Together, these findings establish phosphofructokinase activity as a central node in carbon metabolism and a recurring subject in metabolic, cancer and parasitology research.
phosphofructokinase activity At A Glance
| GO ID | GO:0008443 |
|---|---|
| GO term | phosphofructokinase activity |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Catalysis of the transfer of a phosphate group, usually from ATP, to a phosphofructose substrate molecule |
| Major function | Phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate, the committed step of glycolysis |
| Representative enzymes | PFK-1 tetramers composed of PFKM, PFKL and PFKP subunits |
| Key regulators | ATP, AMP, fructose-2,6-bisphosphate and cellular energy status |
| Tissue context | Skeletal muscle, myocardium, intestinal mucosa and other glucose-consuming tissues |
What Is GO:0008443?
In this article, phosphofructokinase activity (GO:0008443) means the catalytic function of transferring a phosphate group, usually from ATP, onto a phosphofructose substrate molecule. This definition describes an activity rather than a specific gene product, so multiple enzymes and isoenzymes can carry it. The best-characterized example is the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate by PFK-1, but the term is defined by the chemistry of phosphate transfer to a phosphofructose acceptor.
Why Is phosphofructokinase activity Important in Cell Biology?
Phosphofructokinase activity is important because it sets the pace of glycolytic flux and therefore influences ATP production, biosynthetic precursor supply and cellular redox balance. Because the reaction it catalyzes is rate-limiting and effectively irreversible, changes in its activity can redirect glucose carbons between catabolism and biosynthesis, which is why it is a focal point in studies of muscle physiology, cardiac metabolism and cancer. Its sensitivity to acidosis and to physiological conditions also makes it a model for understanding how metabolic enzymes integrate signals from the cellular environment.
• It catalyzes the committed step of glycolysis, controlling whether glucose enters glycolytic catabolism.
• It is allosterically regulated by energy-status signals, allowing flux to match ATP demand.
• Its activity is sensitive to acidosis during short-term tetanic contractions, linking metabolism to muscle fatigue.
• It is examined under physiological conditions in skeletal muscle to understand in vivo regulation.
• It responds to glucose availability in the intestinal mucosa, connecting nutrition to enzyme activity.
• It coordinates biosynthetic pathway activity in the myocardium, linking glycolysis to macromolecule synthesis.
• Its expression and activity are altered in states of changed insulin-stimulated glucose metabolism.
• PFKP, a subunit carrying this activity, can be destabilized by p53-responsive CMBL, suppressing cancer development.
• Inhibition of phosphofructokinase activity contributes to the antischistosomal action of trivalent organic antimonials.
• It is a target for structural and allosteric studies of human PFK-1.
What Happens During phosphofructokinase activity?
Substrate binding and phosphate transfer
In simple terms: The enzyme grabs a sugar phosphate and a phosphate donor, then moves the phosphate onto the sugar.
Phosphofructokinase activity catalyzes the transfer of a phosphate group, usually from ATP, to a phosphofructose substrate molecule. In the canonical PFK-1 reaction, fructose-6-phosphate is phosphorylated to fructose-1,6-bisphosphate, committing the substrate to glycolysis. Structural studies of human PFK-1 provide a basis for understanding how substrate and nucleotide binding are arranged in the active site.
Allosteric regulation by energy status
In simple terms: The enzyme senses whether the cell has enough energy and speeds up or slows down accordingly.
Human PFK-1 is allosterically regulated, and structural analysis has revealed the basis for this regulation. Because the reaction consumes ATP, the enzyme integrates signals of cellular energy charge to match glycolytic flux to demand. This allosteric control is a defining feature of phosphofructokinase activity in physiological settings.
Isoenzyme assembly and subunit composition
In simple terms: Different versions of the enzyme are built from different subunit combinations, which changes how they behave.
Human PFK-1 is a tetramer assembled from PFKM, PFKL and PFKP subunits, and the subunit composition influences the enzyme's catalytic and regulatory properties. Tissue-specific expression of these subunits produces isoenzymes adapted to different metabolic contexts. This compositional diversity is central to interpreting phosphofructokinase activity in different tissues.
Integration with biosynthetic pathways
In simple terms: The enzyme does not work alone; its activity is coordinated with pathways that build cell components.
In vivo deep network tracing in the myocardium revealed phosphofructokinase-mediated coordination of biosynthetic pathway activity. This indicates that phosphofructokinase activity is functionally linked to macromolecule synthesis, not only to ATP production. Such coordination helps explain why glycolytic flux is tuned to biosynthetic demand in tissues such as the heart.
Physiological and pharmacological modulation
In simple terms: Conditions in the body and certain drugs can change how fast this enzyme works.
Phosphofructokinase activity is sensitive to acidosis during short-term tetanic contractions, linking the enzyme to muscle fatigue. It has been examined under physiological conditions in vitro to better approximate in vivo regulation. In the intestinal mucosa, glucose availability affects phosphofructokinase activity, showing nutritional modulation. Inhibition of phosphofructokinase activity is also associated with the mode of action of trivalent organic antimonials on Schistosoma mansoni.
Key Genes Involved in GO:0008443 phosphofructokinase activity
The following genes and proteins are directly or functionally associated with phosphofructokinase activity (GO:0008443) in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PFKM | Encodes the muscle-type subunit of PFK-1, a tetrameric enzyme carrying phosphofructokinase activity | Studied for muscle glycolysis and allosteric regulation |
| PFKL | Encodes the liver-type subunit of PFK-1 | Relevant to tissue-specific isoenzyme composition and regulation |
| PFKP | Encodes the platelet-type subunit of PFK-1 | Targeted for degradation by p53-responsive CMBL in cancer suppression |
| CMBL | p53-responsive protein that destabilizes PFKP | Links p53 signaling to glucose metabolism and cancer development |
| TP53 | Tumor suppressor that induces CMBL, indirectly affecting PFKP stability | Context for p53-responsive metabolic reprogramming |
| ATP | Phosphate donor for the phosphofructokinase reaction | Central to energy-status regulation of the enzyme |
| Fructose-6-phosphate | Phosphofructose substrate phosphorylated by PFK-1 | Substrate for measuring phosphofructokinase activity |
| Fructose-1,6-bisphosphate | Product of the PFK-1 reaction | Readout of glycolytic commitment |
| Insulin signaling pathway components | Alter hexokinase, phosphofructokinase and glycogen synthase expression/activity in skeletal muscle | Model for insulin-stimulated glucose metabolism |
| Myocardial metabolic network | Coordinates biosynthetic pathway activity via phosphofructokinase | In vivo tracing of glycolytic-biosynthetic coupling |
| Skeletal muscle contractile apparatus | Context in which acidosis affects phosphofructokinase activity | Studies of fatigue and short-term tetanic contractions |
| Intestinal mucosa glucose transport machinery | Glucose availability modulates phosphofructokinase activity | Nutritional regulation of glycolytic flux |
| Schistosoma mansoni phosphofructokinase | Parasite enzyme inhibited by trivalent organic antimonials | Antischistosomal drug mechanism studies |
| PFK-1 tetramer | Catalytically active assembly of PFKM, PFKL and PFKP subunits | Structural and allosteric studies |
| Glycolytic enzyme network | Functional network in which phosphofructokinase activity is a control node | Flux analysis and metabolic modeling |
| Biosynthetic pathway enzymes | Coordinated with phosphofructokinase activity in the myocardium | Deep network tracing in vivo |
| Glucose metabolism regulators | Modulate hexokinase, phosphofructokinase and glycogen synthase in altered insulin states | Human skeletal muscle studies |
| Acidosis-sensitive metabolic sensors | Mediate pH effects on phosphofructokinase activity | Physiological studies of contraction and fatigue |
How Is phosphofructokinase activity Regulated?
Phosphofructokinase activity is regulated at multiple levels. Allosteric regulation of human PFK-1 has been characterized structurally, providing a basis for how effectors and energy-status signals modulate the enzyme. In skeletal muscle, phosphofructokinase activity is influenced by acidosis during short-term tetanic contractions, indicating pH-sensitive regulation. The enzyme has also been examined under physiological conditions in vitro to better reflect in vivo regulation. In the intestinal mucosa, glucose availability modulates phosphofructokinase activity, showing substrate- or nutrition-linked regulation. In cancer, PFKP stability is regulated by p53-responsive CMBL, which destabilizes PFKP and thereby affects glucose metabolism. In vivo tracing in the myocardium further indicates that phosphofructokinase activity is coordinated with biosynthetic pathway activity, reflecting network-level regulation.
phosphofructokinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PFKP | Cancer metabolism; p53-responsive CMBL destabilizes PFKP to suppress cancer development | PFKP knockout or point-mutation cancer cell lines with CMBL induction |
| PFKM | Muscle glycolysis and acidosis-related fatigue | PFKM knockout muscle cell models and contraction assays |
| PFKL | Tissue-specific glycolytic regulation | PFKL knockout or knock-in isoenzyme models |
| Insulin signaling genes | Altered insulin-stimulated glucose metabolism in skeletal muscle | Human skeletal muscle cell models with insulin stimulation |
| Schistosoma mansoni PFK | Parasitic infection and antimonial drug action | Parasite enzyme inhibition assays |
Cancer metabolism and PFKP destabilization
p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing PFKP, a subunit that carries phosphofructokinase activity. This links the regulation of phosphofructokinase activity to tumor suppression and suggests that PFKP stability is a node in cancer metabolic reprogramming.
Insulin resistance and altered glucose metabolism
Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle have examined states of altered insulin-stimulated glucose metabolism. These findings connect phosphofructokinase activity to the broader physiology of insulin-sensitive glucose disposal.
Muscle fatigue and acidosis
Phosphofructokinase activity and acidosis during short-term tetanic contractions have been studied together, linking the enzyme to muscle fatigue under intense activity. This work places phosphofructokinase activity in the physiology of contraction and acid-base balance.
Parasitic infection and drug action
The relationship between inhibition of phosphofructokinase activity and the mode of action of trivalent organic antimonials on Schistosoma mansoni has been described, indicating that the parasite enzyme is a drug target. This illustrates how phosphofructokinase activity can be exploited pharmacologically in infectious disease.
From phosphofructokinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PFKP affect cancer cell proliferation? | PFKP knockout in cancer cell lines |
| How does PFKM mutation alter allosteric regulation? | PFKM point-mutation knock-in cell models |
| Can tagged PFK-1 be used to study subunit assembly? | Tagged knock-in of PFKM, PFKL or PFKP |
| Does PFKP overexpression reprogram glucose metabolism? | PFKP overexpression cell models |
| How does phosphofructokinase activity coordinate biosynthetic pathways? | In vivo deep network tracing in myocardium |
| How does glucose availability regulate phosphofructokinase activity? | Intestinal mucosa or glucose-responsive cell models |
How to Study the phosphofructokinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Rate of phosphate transfer to phosphofructose substrate | Comparing phosphofructokinase activity across conditions |
| Structural biology | Allosteric and active-site architecture of PFK-1 | Understanding regulation of human PFK-1 |
| In vivo deep network tracing | Coordination of biosynthetic pathway activity | Myocardial metabolic network studies |
| Gene expression analysis | Expression of hexokinase, phosphofructokinase and glycogen synthase | Human skeletal muscle insulin-state studies |
| Physiological in vitro assay | Phosphofructokinase activity under near-physiological conditions | Skeletal muscle metabolism research |
| Glucose availability experiments | Modulation of phosphofructokinase activity by glucose | Intestinal mucosa studies |
| Pharmacological inhibition | Effect of inhibitors on phosphofructokinase activity | Antischistosomal drug mechanism studies |
| Protein stability assays | PFKP degradation in response to CMBL | Cancer metabolism and p53 pathway research |
Enzyme activity assays
Phosphofructokinase activity can be measured by monitoring the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate, as described in studies of human PFK-1 and in physiological examinations of skeletal muscle. Such assays are used to compare activity across tissues, metabolic states and genetic models.
Structural biology and allostery
Structural analysis of human PFK-1 has provided a basis for understanding allosteric regulation of phosphofructokinase activity. These approaches help map effector binding and subunit interfaces that control catalysis.
Metabolic tracing and network analysis
In vivo deep network tracing has been used to reveal phosphofructokinase-mediated coordination of biosynthetic pathway activity in the myocardium. This method connects enzyme activity to pathway-level metabolic organization.
Genetic and pharmacological perturbation
Studies of PFKP destabilization by p53-responsive CMBL and of phosphofructokinase inhibition by trivalent organic antimonials illustrate genetic and pharmacological perturbation of this activity. These approaches are used to test causality between phosphofructokinase activity and disease phenotypes.
How CRISPR Can Be Used to Study GO:0008443 phosphofructokinase activity
Knockout
CRISPR knockout of PFKM, PFKL or PFKP can be used to eliminate specific subunits of PFK-1 and test how loss of phosphofructokinase activity affects glycolysis, biosynthetic pathways and disease phenotypes. Such models are particularly useful for dissecting subunit-specific contributions to the tetrameric enzyme.
Point Mutation
Point-mutation models can be introduced into PFK genes to probe allosteric regulation and catalytic residues identified by structural studies of human PFK-1. These models help separate catalytic function from regulatory control of phosphofructokinase activity.
Knock-in
Knock-in of tagged or variant PFK subunits allows tracking of enzyme assembly and localization while preserving endogenous regulation. This is valuable for studying how subunit composition influences phosphofructokinase activity in different tissues.
Overexpression
Overexpression of PFKP or other PFK subunits can be used to test whether increased phosphofructokinase activity reprograms glucose metabolism, as suggested by studies of PFKP destabilization in cancer. Overexpression models complement loss-of-function approaches to establish causality.
How EDITGENE Supports phosphofructokinase activity Research
Researchers studying phosphofructokinase activity-related genes often need to determine whether a candidate gene is causally involved in glycolytic flux, biosynthetic coordination or disease phenotypes, and CRISPR-based models provide a direct way to test this. EDITGENE supports this work with knockout, point-mutation, knock-in and overexpression cell models, as well as CRISPR library screening and bioinformatics services tailored to metabolic and cancer research.
Contact EDITGENE today to design your custom CRISPR model for phosphofructokinase activity research.
Frequently Asked Questions About phosphofructokinase activity
What is phosphofructokinase activity?
Phosphofructokinase activity (GO:0008443) is a molecular_function defined as catalysis of the transfer of a phosphate group, usually from ATP, to a phosphofructose substrate molecule.
What does GO:0008443 mean?
GO:0008443 is the Gene Ontology identifier for phosphofructokinase activity, a molecular_function term describing phosphate transfer to a phosphofructose substrate.
What genes are involved in phosphofructokinase activity?
Human PFK-1 is assembled from PFKM, PFKL and PFKP subunits, and PFKP stability is regulated by p53-responsive CMBL.
Why is phosphofructokinase activity important in glycolysis?
It catalyzes the committed step of glycolysis, phosphorylating fructose-6-phosphate to fructose-1,6-bisphosphate and controlling glycolytic flux.
How is phosphofructokinase activity regulated?
It is allosterically regulated, sensitive to acidosis in muscle, modulated by glucose availability in intestinal mucosa, and affected by PFKP destabilization in cancer.
Is phosphofructokinase activity linked to cancer?
Yes, p53-responsive CMBL destabilizes PFKP and suppresses cancer development by reprogramming glucose metabolism.
How can I measure phosphofructokinase activity?
Enzyme activity assays measuring phosphate transfer to phosphofructose substrates are commonly used, along with structural and metabolic tracing approaches.
What is the role of PFKP in phosphofructokinase activity?
PFKP encodes the platelet-type subunit of PFK-1, and its stability influences glucose metabolism and cancer development.
Can CRISPR be used to study phosphofructokinase activity?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models can be used to dissect PFK gene function and regulation.
Is phosphofructokinase activity a drug target?
Inhibition of phosphofructokinase activity is linked to the antischistosomal action of trivalent organic antimonials on Schistosoma mansoni.
Conclusion
Phosphofructokinase activity (GO:0008443) is a central molecular_function in glucose metabolism, catalyzing phosphate transfer to a phosphofructose substrate and controlling the committed step of glycolysis. Its regulation by allostery, energy status, pH and nutritional cues makes it a sensitive node in muscle, cardiac and intestinal physiology. In disease, PFKP destabilization by p53-responsive CMBL links phosphofructokinase activity to cancer suppression, while inhibition of the parasite enzyme underlies antischistosomal drug action. CRISPR-based models of PFK genes provide a direct route to test causality and to develop new therapeutic hypotheses around this activity.
References
- 1. Spriet LL. 1991. Phosphofructokinase activity and acidosis during short-term tetanic contractions.. Can J Physiol Pharmacol 69(2):298-304 PMID: 1829021
- 2. Lynch EM et al.. 2024. Structural basis for allosteric regulation of human phosphofructokinase-1.. Nat Commun 15(1):7323 PMID: 39183237
- 3. Vestergaard H. 1999. Studies of gene expression and activity of hexokinase, phosphofructokinase and glycogen synthase in human skeletal muscle in states of altered insulin-stimulated glucose metabolism.. Dan Med Bull 46(1):13-34 PMID: 10081651
- 4. Fulghum KL et al.. 2022. In vivo deep network tracing reveals phosphofructokinase-mediated coordination of biosynthetic pathway activity in the myocardium.. J Mol Cell Cardiol 162:32-42 PMID: 34487754
- 5. Huang Y et al.. 2023. p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP.. Cell Rep 42(11):113426 PMID: 37967006
- 6. Peters SJ et al.. 1995. Skeletal muscle phosphofructokinase activity examined under physiological conditions in vitro.. J Appl Physiol (1985) 78(5):1853-8 PMID: 7649922
- 7. Jamal A et al.. 1984. The effect of glucose on the activity of phosphofructokinase in the mucosa of rat small intestine.. Biochem J 218(2):459-64 PMID: 6231923
- 8. BUEDING E et al.. 1957. The relationship between inhibition of phosphofructokinase activity and the mode of action of trivalent organic antimonials on Schistosoma mansoni.. Br J Pharmacol Chemother 12(2):159-65 PMID: 13446367
